Therapy

Halozyme Therapeutics

$49.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.00 (+4.21%) Today
$0.00 (0.00%) As of 11:35 AM UTC after-hours

Why Robinhood?

You can buy or sell HALO and other stocks, options, and ETFs commission-free!

About HALO

Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. The listed name for HALO is Halozyme Therapeutics, Inc. Common Stock.

CEO
Helen I. Torley
Employees
132
Headquarters
San Diego, California
Founded
1998
Market Cap
6.72B
Price-Earnings Ratio
322.69
Dividend Yield
—
Average Volume
1.51M
High Today
$49.55
Low Today
$46.75
Open Price
$46.78
Volume
947.12K
52 Week High
$49.55
52 Week Low
$12.71

Collections

HALO Earnings

-$0.24
-$0.08
$0.09
$0.25
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 23, After Hours

You May Also Like

WMS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure